Category: Covid-19

This reporting protocol describes data collection for human cases of zoonotic influenza viruses, with the aim to support assessment of key indicators and trends over time and inform situational risk assessments.

This reporting protocol describes data collection for human cases of zoonotic influenza viruses, with the aim to support assessment of key indicators and trends over time and inform situational risk assessments.

At the EU/EEA level, influenza activity continues to increase while RSV activity is decreasing. Vaccination campaigns against respiratory pathogens continue in many EU/EEA countries and people who are eligible for vaccination, particularly those at higher risk of severe outcomes, are encouraged to get vaccinated.

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 11 – 17 January 2025 and includes updates on respiratory virus epidemiology in the EU/EEA, mpox, influenza, cholera, Marburg virus, rabies, and chikungunya, measles, polio, MRSA, and mass gathering monitoring for the Jubilee of 2025 in Italy.

In the EU/EEA, both influenza and RSV activity is increasing.

In the EU/EEA, both influenza and RSV epidemics are ongoing in several countries. Vaccination campaigns against respiratory pathogens have started in many EU/EEA countries. People who are eligible for vaccination, particularly those at higher risk of severe outcomes, are encouraged to get vaccinated.

The Chinese Centre for Disease Control and Prevention (CDC) has reported a sharp increase in respiratory viral infections, including human metapneumovirus (hMPV) infections, in northern China since December 2024.

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 14-20 December 2024 and includes updates on Cyclone Chido, Mpox due to monkeypox virus clade I and II, SARS-CoV-2 variant classification, Overview of respiratory virus epidemiology in the EU/EEA, Marburg virus disease and Avian influenza A(H5N1).

Almost all countries reporting data to ECDC are observing sharp increases in indicators of both influenza and respiratory syncytial virus (RSV) activity, with a visible impact in secondary care.

This core protocol for ECDC studies of VE against hospitalisation with SARI laboratory-confirmed with SARS-CoV-2 or with influenza, version 4.0, represents an update to the main elements for a multi-country hospital-based study of COVID-19 vaccine effectiveness in patients hospitalised with SARI, initially published as version 1.0.